Baseline characteristics and follow-up
| Characteristic . | Cohort 1 . | Cohort 2 . | Total . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| No. of patients | 105 | 105 | 210 | |||
| Age, years | ||||||
| Median | 48 | 49 | 48.5 | |||
| Range | 16-81 | 17-79 | 16-81 | |||
| Female | 51 | 49 | 41 | 39 | 92 | 44 |
| Follow-up, months | ||||||
| Median | 50 | 32 | 40 | |||
| Range | 40-65 | 24-40 | 24-65 | |||
| Sokal risk score | ||||||
| High | 23 | 14 | 19 | |||
| Intermediate | 32 | 30 | 31 | |||
| Low | 41 | 50 | 46 | |||
| Unknown | 4 | 5 | 5 | |||
| Characteristic . | Cohort 1 . | Cohort 2 . | Total . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| No. of patients | 105 | 105 | 210 | |||
| Age, years | ||||||
| Median | 48 | 49 | 48.5 | |||
| Range | 16-81 | 17-79 | 16-81 | |||
| Female | 51 | 49 | 41 | 39 | 92 | 44 |
| Follow-up, months | ||||||
| Median | 50 | 32 | 40 | |||
| Range | 40-65 | 24-40 | 24-65 | |||
| Sokal risk score | ||||||
| High | 23 | 14 | 19 | |||
| Intermediate | 32 | 30 | 31 | |||
| Low | 41 | 50 | 46 | |||
| Unknown | 4 | 5 | 5 | |||